U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Refractory Malignant Thyroid Gland Neoplasm

MedGen UID:
1657852
•Concept ID:
C4725815
•
Neoplastic Process

Definition

Malignant thyroid gland neoplasm that is resistant to treatment. [from NCI]

Professional guidelines

PubMed

Molecular diagnosis and targeted treatment of advanced follicular cell-derived thyroid cancer in the precision medicine era.
Capdevila J, Awada A, Führer-Sakel D, Leboulleux S, Pauwels P
Cancer Treat Rev 2022 May;106:102380. Epub 2022 Mar 15 doi: 10.1016/j.ctrv.2022.102380. PMID: 35305441
Lenvatinib dose, efficacy, and safety in the treatment of multiple malignancies.
Motzer RJ, Taylor MH, Evans TRJ, Okusaka T, Glen H, Lubiniecki GM, Dutcus C, Smith AD, Okpara CE, Hussein Z, Hayato S, Tamai T, Makker V
Expert Rev Anticancer Ther 2022 Apr;22(4):383-400. Epub 2022 Apr 7 doi: 10.1080/14737140.2022.2039123. PMID: 35260027Free PMC Article
Differentiated Thyroid Cancer-Treatment: State of the Art.
Schmidbauer B, Menhart K, Hellwig D, Grosse J
Int J Mol Sci 2017 Jun 17;18(6) doi: 10.3390/ijms18061292. PMID: 28629126Free PMC Article

Recent clinical studies

Etiology

Summary and update on the management of differentiated thyroid cancer in 2023.
Raymond P, Klein M, Borson-Chazot F
Ann Endocrinol (Paris) 2024 Apr;85(2):110-117. Epub 2024 Feb 3 doi: 10.1016/j.ando.2023.11.007. PMID: 38316254
Update on iodine-refractory differentiated thyroid carcinoma.
Abou Jokh Casas E, Repetto A, Rodriguez Gasén A, Vercher Conejero JL, Bello Arques P, Cambil Molina T, Vallejo Casas JA
Rev Esp Med Nucl Imagen Mol (Engl Ed) 2023 Sep-Oct;42(5):325-334. Epub 2023 Jul 11 doi: 10.1016/j.remnie.2023.07.003. PMID: 37442524
Redifferentiation of radioiodine-refractory thyroid cancers.
Buffet C, Wassermann J, Hecht F, Leenhardt L, Dupuy C, Groussin L, Lussey-Lepoutre C
Endocr Relat Cancer 2020 May;27(5):R113-R132. doi: 10.1530/ERC-19-0491. PMID: 32191916
Treatment of refractory thyroid cancer.
Berdelou A, Lamartina L, Klain M, Leboulleux S, Schlumberger M
Endocr Relat Cancer 2018 Apr;25(4):R209-R223. Epub 2018 Jan 25 doi: 10.1530/ERC-17-0542. PMID: 29371330
Lenvatinib versus placebo in radioiodine-refractory thyroid cancer.
Schlumberger M, Tahara M, Wirth LJ, Robinson B, Brose MS, Elisei R, Habra MA, Newbold K, Shah MH, Hoff AO, Gianoukakis AG, Kiyota N, Taylor MH, Kim SB, Krzyzanowska MK, Dutcus CE, de las Heras B, Zhu J, Sherman SI
N Engl J Med 2015 Feb 12;372(7):621-30. doi: 10.1056/NEJMoa1406470. PMID: 25671254

Diagnosis

The Role of Molecular Markers in Thyroid Cancer Diagnostics and Treatment.
Sada A, Yip L
Surg Clin North Am 2024 Aug;104(4):741-749. Epub 2024 Mar 23 doi: 10.1016/j.suc.2024.02.004. PMID: 38944495
Use of multikinase inhibitors/lenvatinib in singular thyroid cancer scenarios.
Zafón C, Castelo B
Cancer Med 2022 Oct;11 Suppl 1(Suppl 1):3-4. doi: 10.1002/cam4.5154. PMID: 36202604Free PMC Article
Kinase-inhibitors for iodine-refractory differentiated thyroid cancer: still far from a structured therapeutic algorithm.
Marotta V, Chiofalo MG, Di Gennaro F, Daponte A, Sandomenico F, Vallone P, Costigliola L, Botti G, Ionna F, Pezzullo L
Crit Rev Oncol Hematol 2021 Jun;162:103353. Epub 2021 May 14 doi: 10.1016/j.critrevonc.2021.103353. PMID: 34000414
Personalized treatment for differentiated thyroid cancer: current data and new perspectives.
Colombo C, Giancola N, Fugazzola L
Minerva Endocrinol (Torino) 2021 Mar;46(1):62-89. Epub 2020 Nov 19 doi: 10.23736/S2724-6507.20.03342-8. PMID: 33213119
Redifferentiation of radioiodine-refractory thyroid cancers.
Buffet C, Wassermann J, Hecht F, Leenhardt L, Dupuy C, Groussin L, Lussey-Lepoutre C
Endocr Relat Cancer 2020 May;27(5):R113-R132. doi: 10.1530/ERC-19-0491. PMID: 32191916

Therapy

Update on iodine-refractory differentiated thyroid carcinoma.
Abou Jokh Casas E, Repetto A, Rodriguez Gasén A, Vercher Conejero JL, Bello Arques P, Cambil Molina T, Vallejo Casas JA
Rev Esp Med Nucl Imagen Mol (Engl Ed) 2023 Sep-Oct;42(5):325-334. Epub 2023 Jul 11 doi: 10.1016/j.remnie.2023.07.003. PMID: 37442524
A Randomized Study of Lenvatinib 18 mg vs 24 mg in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer.
Brose MS, Panaseykin Y, Konda B, de la Fouchardiere C, Hughes BGM, Gianoukakis AG, Joo Park Y, Romanov I, Krzyzanowska MK, Leboulleux S, Binder TA, Dutcus C, Xie R, Taylor MH
J Clin Endocrinol Metab 2022 Feb 17;107(3):776-787. doi: 10.1210/clinem/dgab731. PMID: 34664662Free PMC Article
Radioiodine-refractory thyroid cancer: a complex challenge.
Vitale G, Pellegrino G, Desiderio E, Barrea L
Minerva Med 2021 Dec;112(6):686-688. Epub 2021 Oct 21 doi: 10.23736/S0026-4806.21.07845-9. PMID: 34672171
Theranostics in Thyroid Cancer.
Eilsberger F, Pfestroff A
PET Clin 2021 Jul;16(3):375-382. doi: 10.1016/j.cpet.2021.03.007. PMID: 34053581
Treatment of refractory thyroid cancer.
Berdelou A, Lamartina L, Klain M, Leboulleux S, Schlumberger M
Endocr Relat Cancer 2018 Apr;25(4):R209-R223. Epub 2018 Jan 25 doi: 10.1530/ERC-17-0542. PMID: 29371330

Prognosis

Summary and update on the management of differentiated thyroid cancer in 2023.
Raymond P, Klein M, Borson-Chazot F
Ann Endocrinol (Paris) 2024 Apr;85(2):110-117. Epub 2024 Feb 3 doi: 10.1016/j.ando.2023.11.007. PMID: 38316254
Update on iodine-refractory differentiated thyroid carcinoma.
Abou Jokh Casas E, Repetto A, Rodriguez Gasén A, Vercher Conejero JL, Bello Arques P, Cambil Molina T, Vallejo Casas JA
Rev Esp Med Nucl Imagen Mol (Engl Ed) 2023 Sep-Oct;42(5):325-334. Epub 2023 Jul 11 doi: 10.1016/j.remnie.2023.07.003. PMID: 37442524
Single-cell transcriptomic analysis of the tumor ecosystems underlying initiation and progression of papillary thyroid carcinoma.
Pu W, Shi X, Yu P, Zhang M, Liu Z, Tan L, Han P, Wang Y, Ji D, Gan H, Wei W, Lu Z, Qu N, Hu J, Hu X, Luo Z, Li H, Ji Q, Wang J, Zhang X, Wang YL
Nat Commun 2021 Oct 18;12(1):6058. doi: 10.1038/s41467-021-26343-3. PMID: 34663816Free PMC Article
Current Treatment Strategies in Metastasized Differentiated Thyroid Cancer.
Kreissl MC, Janssen MJR, Nagarajah J
J Nucl Med 2019 Jan;60(1):9-15. Epub 2018 Sep 6 doi: 10.2967/jnumed.117.190819. PMID: 30190306
Pembrolizumab (Keytruda).
Kwok G, Yau TC, Chiu JW, Tse E, Kwong YL
Hum Vaccin Immunother 2016 Nov;12(11):2777-2789. Epub 2016 Jul 11 doi: 10.1080/21645515.2016.1199310. PMID: 27398650Free PMC Article

Clinical prediction guides

Novel Inhibitor-Based Therapies for Thyroid Cancer-An Update.
Ratajczak M, Gaweł D, Godlewska M
Int J Mol Sci 2021 Oct 31;22(21) doi: 10.3390/ijms222111829. PMID: 34769260Free PMC Article
Pembrolizumab (Keytruda).
Kwok G, Yau TC, Chiu JW, Tse E, Kwong YL
Hum Vaccin Immunother 2016 Nov;12(11):2777-2789. Epub 2016 Jul 11 doi: 10.1080/21645515.2016.1199310. PMID: 27398650Free PMC Article
Lenvatinib in Advanced, Radioactive Iodine-Refractory, Differentiated Thyroid Carcinoma.
Yeung KT, Cohen EE
Clin Cancer Res 2015 Dec 15;21(24):5420-6. Epub 2015 Oct 20 doi: 10.1158/1078-0432.CCR-15-0923. PMID: 26487760
Lenvatinib versus placebo in radioiodine-refractory thyroid cancer.
Schlumberger M, Tahara M, Wirth LJ, Robinson B, Brose MS, Elisei R, Habra MA, Newbold K, Shah MH, Hoff AO, Gianoukakis AG, Kiyota N, Taylor MH, Kim SB, Krzyzanowska MK, Dutcus CE, de las Heras B, Zhu J, Sherman SI
N Engl J Med 2015 Feb 12;372(7):621-30. doi: 10.1056/NEJMoa1406470. PMID: 25671254
The prognostic implications from molecular testing of thyroid cancer.
Ozgursoy OB, Eisele DW, Tufano RP
Otolaryngol Clin North Am 2014 Aug;47(4):595-607. doi: 10.1016/j.otc.2014.04.010. PMID: 25041960

Recent systematic reviews

Efficacy and Safety of Multikinase Inhibitors for Patients With Refractory Thyroid Cancer: Systematic Review and Network Meta-Analysis.
Jing R, Wu N, Wu Y, Zhang Q, Liang Q, Huang P, Yi S
J Clin Endocrinol Metab 2024 Sep 16;109(10):2658-2672. doi: 10.1210/clinem/dgae454. PMID: 38970485
Tyrosine kinase inhibitors for radioiodine refractory differentiated thyroid cancer: A systematic review and meta-analysis.
Yu J, Liu Z, Su Y, Peng X, Xie Y
Clin Endocrinol (Oxf) 2024 Apr;100(4):379-388. Epub 2024 Feb 13 doi: 10.1111/cen.15027. PMID: 38351437
Vitamin D-Related Genes and Thyroid Cancer-A Systematic Review.
Maciejewski A, Lacka K
Int J Mol Sci 2022 Nov 7;23(21) doi: 10.3390/ijms232113661. PMID: 36362448Free PMC Article
Sorafenib and radioiodine-refractory differentiated thyroid cancer (RR-DTC): a systematic review and meta-analysis.
Feng G, Luo Y, Zhang Q, Zeng F, Xu J, Zhu J
Endocrine 2020 Apr;68(1):56-63. Epub 2020 Jan 18 doi: 10.1007/s12020-019-02167-6. PMID: 31955344
Differentiated Thyroid Cancer-Treatment: State of the Art.
Schmidbauer B, Menhart K, Hellwig D, Grosse J
Int J Mol Sci 2017 Jun 17;18(6) doi: 10.3390/ijms18061292. PMID: 28629126Free PMC Article

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...